Biopharmaceutical research divisions are integrating structural analysis tools to evaluate protein target viability prior to wet-lab testing. The technology accelerates lead optimization phases, significantly cutting early-stage discovery costs.
Clinical Development Efficiency
By filtering non-viable molecular candidates earlier, research teams are improving phase-one transition rates by an estimated 14%. Major pharmaceutical firms are reallocating resultant savings into late-stage clinical trial execution.